Stock TAK N TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited Mexican S.E.

Equities

TAK N

US8740602052

End-of-day quote Mexican S.E.
Other stock markets
 06:00:00 2024-06-19 pm EDT 		5-day change 1st Jan Change
231.5 MXN -3.73% Intraday chart for Takeda Pharmaceutical Company Limited -3.73% -3.42%
08:50am Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes MT
07:47am Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analyst opinion has improved significantly over the past four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an expected P/E ratio at 45.24 and 69.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
-3.42% 39.77B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.99% 798B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.72% 356B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.94% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+11.07% 304B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.19% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.94% 227B
A+
NOVARTIS AG Stock Novartis AG
+11.35% 216B
B-
AMGEN INC. Stock Amgen Inc.
+7.59% 166B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.65% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TAK N Stock
  5. Ratings Takeda Pharmaceutical Company Limited